Dr James Murray has been with Vernalis since 2001 having previously held research roles in the USA and Australia. Throughout this period, James has guided the evolution of our approach to drug discovery, with a particular emphasis on the role of biophysics across a wide range of target classes.
He co-led the discovery of multiple candidates in collaboration with pharma and biotech companies, most notably BH3 mimetics targeting Mcl-1 and Bcl-2. He has over 60 peer reviewed scientific papers and, 13 granted patents and more than 20 active patent applications.
James champions an open and inclusive approach to the Vernalis research culture, which is reflected in how we collaborate.
